Bruker Corporation (NASDAQ:BRKR) Receives Average Recommendation of “Hold” from Analysts

Shares of Bruker Corporation (NASDAQ:BRKR) have been assigned an average rating of “Hold” from the seventeen brokerages that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $51.50.

A number of research analysts have commented on the company. Rothschild Redb upgraded Bruker to a “strong-buy” rating in a research note on Thursday, November 20th. Cowen reaffirmed a “hold” rating on shares of Bruker in a report on Tuesday, November 4th. Redburn Partners set a $60.00 price objective on shares of Bruker in a report on Thursday, November 20th. The Goldman Sachs Group started coverage on Bruker in a research note on Tuesday, December 9th. They set a “sell” rating and a $40.00 target price on the stock. Finally, Rothschild & Co Redburn assumed coverage on shares of Bruker in a research note on Thursday, November 20th. They issued a “buy” rating and a $60.00 price target for the company.

Bruker Stock Up 2.8%

Shares of NASDAQ:BRKR opened at $52.67 on Wednesday. The stock has a 50-day simple moving average of $45.20 and a 200-day simple moving average of $39.45. The stock has a market capitalization of $8.00 billion, a P/E ratio of -329.19, a PEG ratio of 6.64 and a beta of 1.17. Bruker has a 1 year low of $28.53 and a 1 year high of $64.64. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.91 and a current ratio of 1.85.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.33 by $0.12. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The firm had revenue of $860.50 million for the quarter, compared to analyst estimates of $847.40 million. During the same quarter last year, the firm posted $0.60 earnings per share. Bruker’s revenue for the quarter was down .5% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. Equities analysts forecast that Bruker will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, January 2nd. Investors of record on Monday, December 8th were issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date was Monday, December 8th. Bruker’s payout ratio is presently -125.00%.

Insiders Place Their Bets

In related news, Director John A. Ornell sold 6,233 shares of Bruker stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $39.00, for a total value of $243,087.00. Following the transaction, the director owned 35,212 shares of the company’s stock, valued at approximately $1,373,268. This trade represents a 15.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 27.30% of the company’s stock.

Institutional Investors Weigh In On Bruker

Several hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC lifted its holdings in shares of Bruker by 377.5% in the second quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 487 shares in the last quarter. Allworth Financial LP lifted its position in shares of Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after purchasing an additional 257 shares in the last quarter. Huntington National Bank grew its holdings in shares of Bruker by 750.0% during the 2nd quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 645 shares in the last quarter. Spire Wealth Management purchased a new stake in shares of Bruker during the 2nd quarter worth about $32,000. Finally, Parallel Advisors LLC grew its position in Bruker by 63.0% in the second quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock worth $37,000 after acquiring an additional 347 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.